|
⚲
|
| Stemline Therapeutics Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001264587 |
| Sale | 2010-03-16 ($1.2 M Offered, $1.2 M Sold) |
| Fund | |
| Phone | 2125315969 |
| Address | 1675 York Avenue, Suite 34L New York, 10128 |
| Source | [EDGAR] |
| Fund AUM and Sold ($k) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Form D Offering | |
|---|---|
| Filed | 2010-03-29 (D) |
| Exemption | 506 |
| Duration | One year or less |
| Revenue | Decline to Disclose |
| Directors | Role | 2011 - 2026 |
|---|---|---|
| Ronald Bentsur | Director | |
| Ivan Bergstein | Executive Officer |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Respiderm Corp
✚
|
0.0 | |
|
Revetas Capital III Co-Invest GS II SCSp
✚
|
0.0 | |
|
Revetas Capital III Co-Invest GS SCSp
✚
|
0.0 | |
|
Reyes Carla
✚
|
0.0 | |
|
Reynolds Donald Rogers
✚
|
0.0 | |
|
Reynolds Elizabeth E
✚
|
0.0 | |
|
Rezaei Jamshid
✚
|
0.0 | |
|
Richesson Kirsten E
✚
|
0.0 | |
|
Richter David Scott
✚
|
0.0 | |
|
Resource Maryland LLC
✚
|
0.0 |